ISTANBUL, June 12, 2026 /PRNewswire/ -- At the recently concluded KOMATEK 2026 exhibition, Zoomlion Heavy Industry Science & Technology Co., Ltd. ("Zoomlion"; 1157.HK) made a powerful impression under the theme "Innovation for Value". Showcasing over 40 advanced products alongside its localized sales and service framework, the company garnered extensive acclaim from global customers. During the event, Zoomlion secured over 1 billion RMB (approx. $138 million USD) in new and intentional orders, highlighting its market leading position and the rapid momentum of its international development.

Localization and customization stood out as core features of Zoomlion's exhibition lineup. To address the rigorous operating conditions and regulatory frameworks of Turkey and its surrounding markets, the company presented several tailored equipment solutions. A key highlight was the ZLK7600V803 knuckle boom crane, a specialized model manufactured locally at Zoomlion's factory in Germany. The crane features a superstructure manufactured by Zoomlion's German subsidiary, WILBERT, integrated with a premium, locally sourced European Scania chassis. Fully certified under CE standards and meeting all European road transport regulations, this model seamlessly blends Zoomlion's long-standing structural optimization and control technologies. Offering exceptional lifting performance, high quality, and cost-efficiency, this benchmark machine serves as a compelling example of Zoomlion's "global village mindset" in driving international industrial collaboration and deeper market integration.

This deep integration of cross-border technological innovation and overseas localized manufacturing is a direct result of Zoomlion's "1+N" global manufacturing strategy. Under this blueprint, "1" represents the Zoomlion Smart City in China—the central hub for advanced research and primary exporter of core technologies and innovative products. The "N" signifies a growing network of overseas localized manufacturing facilities and service platforms positioned across key strategic markets worldwide. Currently, Zoomlion has established 13 overseas R&D and manufacturing bases, more than 30 primary regional aviation hubs, and over 400 sales and service outlets, with its products and services covering over 170 countries and regions. Through this expansive network, Zoomlion is constructing a highly collaborative global industrial framework.

As one of Zoomlion's core strategic markets, Turkey exemplifies this deeply localized approach. Since establishing its Istanbul subsidiary in 2018, Zoomlion has built a robust network of 12 comprehensive service branches and 3 central warehouses across the country. The recent openings of the Denizli branch (3,500 sq. m.) and the Bursa branch (1,200 sq. m.) have further solidified Zoomlion's capability to serve as a critical regional hub for sales, technical maintenance, and spare parts. This extensive direct infrastructure effectively establishes an integrated "end-to-end" platform combining administration, warehousing, logistics, and customer support for the region.

Concurrently, Zoomlion is extending its localized manufacturing capabilities deeper into Europe. In Tatabánya, Hungary, Zoomlion's modern AWP intelligent factory officially commenced Phase I operations in 2026. Strategically positioned at a major logistics corridor connecting Eastern and Western Europe, this 250-mu (approx. 16.5-hectare) facility specializes in high-quality boom and scissor lifts. This setup significantly enhances regional supply chain efficiency and product availability while fostering strong, mutually beneficial synergies with local industrial ecosystems.

Meanwhile, Zoomlion is driving a landmark transformation at its primary European manufacturing hub in Germany. Following the acquisition of tower crane manufacturer WILBERT in 2018, the site has steadily evolved into a multi-category industrial base. In 2025, Zoomlion broke ground on Phase II of the factory, an investment exceeding EUR 50 million covering over 60,000 square meters. Upon reaching full capacity, the expanded facility will produce over 1,000 units of tower cranes, mobile cranes, and concrete machinery annually, serving as a comprehensive overseas production hub and a vital bridgehead for Zoomlion's long-term growth in Europe.

The rollout of the "1+N" strategy delivers distinct operational advantages to both Zoomlion and its global customers. First, it significantly improves delivery efficiency and product adaptability, as manufacturing and assembling equipment closer to end markets allows Zoomlion to respond more swiftly to regional standards and customer preferences. Second, closer coordination among these global bases enhances supply chain resilience. Through mutual resource integration between domestic and overseas facilities, Zoomlion has optimized regional logistics networks and ensured a stable, consistent, and reliable product supply for international construction machinery markets. Finally, supported by an end-to-end service network and direct direct-to-customer operations, Zoomlion provides comprehensive lifecycle maintenance support, building deep commercial trust and establishing a solid foundation for mutual success with global clients.

From product innovation to intelligent manufacturing, and from local production to direct service support, Zoomlion continues to root itself in local markets with a "global village mindset". Driven by continuous technological R&D and localized operations, the company refines its products to match global needs while strengthening connections worldwide. Moving forward, Zoomlion remains committed to open cooperation, leveraging its industry-leading R&D capabilities, comprehensive manufacturing systems, and professional service networks to work alongside global customers and partners toward a sustainable future.

——  11% above WLTP to 646 km and 12m55s charge secure double victory at NAF El Prix Summer 2026

AMSTERDAM, June 12, 2026 /PRNewswire/ -- The XPENG X9 recorded the largest positive deviation from WLTP range and the fastest charging time among all vehicles tested in the summer edition of El Prix 2026, the world's largest independent electric vehicle test organised by the Norwegian Automobile Federation (NAF) and Motor magazine.

The seven-seater achieved the highest result among all 24 vehicles tested, delivering a leading 11.4% positive deviation versus its official WLTP range. In real-world conditions, it covered a total of 646 km and continued operating for more than 11 hours after the start of the test. NAF noted that the XPENG X9 "clearly stood out" in this year's range evaluation.

The X9 also delivered the fastest charging performance, going from 10% to 80% in 12 minutes and 55 seconds. At the El Prix Winter 2026 held in February, the model again topped the field at -10°C with a 12-minute charge. While Europe's current 400 kW charging infrastructure has yet to fully unlock the X9's maximum capability, the vehicle continues to achieve top-tier charging times across different environments.

The result makes the XPENG X9 the standout performer of El Prix and further demonstrates the real world benefits of XPENG's latest generation EV technology.

"Recording the largest WLTP range deviation and the fastest charging time is strong validation of the technology behind the XPENG X9," said Alex Tang, General Manager of International Business at XPENG. "Customers should not have to choose between long range and fast charging. The X9 delivers both, helping drivers spend more time on the road and less time waiting at a charger."

Held twice a year, El Prix is widely regarded as the world's largest independent comparison of electric vehicle range and charging performance. The results are closely followed by consumers, media and manufacturers across Europe. 

The XPENG X9 is one of new XPENG models launching in Europe during 2026, with Norway serving as the first market. Combining long range capability, ultra‑fast charging and premium comfort for up to seven passengers, it plays a key role in XPENG's continued growth ambitions across one of the world's most advanced EV regions.

About XPENG

Founded in 2014, XPENG is a leading Chinese-born AI-driven mobility company that designs, develops, manufactures, and markets Smart EVs, catering to a growing base of tech-savvy consumers. With the rapid advancement of AI, XPENG aspires to become a global leader in AI mobility, with a mission to drive the Smart EV revolution through cutting-edge technology, shaping the future of mobility. To enhance the customer experience, XPENG develops its full-stack advanced driver-assistance system (ADAS) technology and intelligent in-car operating system in-house, along with core vehicle systems such as the powertrain and electrical/electronic architecture (EEA). Headquartered in Guangzhou, China, XPENG also operates key offices in Beijing, Shanghai, Silicon Valley, and Amsterdam. Its Smart EVs are primarily manufactured at its facilities in Zhaoqing and Guangzhou, Guangdong province.

XPENG is listed at the New York Stock Exchange (NYSE: XPEV) and Hong Kong Exchange (HKEX: 9868).

For more information, please visit https://www.xpeng.com/.

Media Contacts
XPENG PR Department
Email: [email protected]

NVIDIA Corporation (NVDA.US) informed Chinese clients that its Vera central processing unit (CPU) for AI data centers could be launched as early as August, with customers able to start placing orders, Reuters, citing sources, reported.

CEO Jensen Huang said in October last year that the company’s market share in China had effectively fallen to zero, under the influence of US export controls on advanced chips.

Some Chinese clients have shown interest in Vera, NVIDIA’s first CPU designed for agentic AI, sources divulged. Vera is now in full production and operates 1.8x faster than comparable processors from competitors.

When Huang unveiled Vera in March, the company said leading cloud computing enterprises, including BABA-W (09988.HK) and ByteDance, were working with NVIDIA to deploy Vera, though it is unclear whether the actual ordering process has begun.
~

AASTOCKS Financial News
Website: www.aastocks.com

HONG KONG, June 12, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that the National Medical Products Administration (NMPA) of China has approved gumokimab (AK111), the company's internally-developed anti-IL-17 monoclonal antibody, for the treatment of adult patients with moderate-to-severe plaque psoriasis.

The approval was supported by one pivotal Phase III clinical study (AK111-301) and three supportive studies. Study results demonstrate gumokimab's rapid and robust efficacy, durable complete skin clearance, and favorable safety and dosing profile. Treatment demonstrated rapid onset of action, with clinically meaningful improvement observed as early as Week 2.

• Rapid and robust efficacy at Week 12: Gumokimab achieved a PASI 75 response rate of 94.6% and a complete skin clearance rate (PASI 100) of 47.7%, substantially higher than the 28.6% PASI 100 response rate observed with other agents in the same class.
• Durable complete clearance through Week 52: The PASI 75 response rate approached 100%, while the PASI 100 response rate reached 68.9%, markedly higher than the 39.2% reported for other drugs in the same class.
• Favorable safety profile: The incidences of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and infections/infestations were numerically among the lowest rates of TEAEs, SAEs, and infections/infestations reported in pivotal trials of IL-17-inhibitors.
• Convenient dosing regimen: Gumokimab utilizes a convenient subcutaneous dosing regimen requiring only 17 injections annually (including loading phase), approximately half the annual injection burden of other IL-17 inhibitors that require more frequent maintenance dosing. Reduced injection frequency has the potential to improve long-term adherence and persistence in moderate-to-severe plaque psoriasis.

Professor Xu Jinhua, Principal Investigator of the pivotal Phase III registration study for gumokimab at Huashan Hospital, Fudan University:

"Psoriasis is a chronic, lifelong condition that demands long-term standardized management. Beyond the physical burden of skin lesions, it significantly impairs patients' quality of life, work, social functioning, and mental well-being. Achieving deep and sustained skin clearance with good tolerability remains a major unmet need. Gumokimab, an IgG1 monoclonal antibody that precisely targets IL-17, has demonstrated rapid onset, strong short-term efficacy, durable long-term control, and a favorable safety profile in clinical studies. We are delighted by its approval, which offers patients a more effective, convenient, and reliable new treatment option."

Dr. Xia Yu, Founder, Chairwoman, President and CEO of Akeso:

"I would like to thank all the investigators, study teams, and patients who participated in the clinical development of gumokimab. Their contributions have enabled us to deliver this important new therapy to the approximately 6.7 million psoriasis patients.

To better address patients' diverse needs, Akeso has successfully developed and launched ebdarokimab and gumokimab, two therapies targeting distinct pathogenic pathways that complement each other. The autoimmune disease field remains one of the largest and fastest-growing areas in innovative drug development. With these two approvals, we have built a strong, differentiated portfolio for psoriasis. Manfidokimab is advancing in late-stage development across multiple indications, while our first-in-class IL-4R/ST2 bispecific antibody AK139 and other novel agents continue to progress rapidly. This growing immunology and inflammation platform is enhancing product synergies and strengthening Akeso's global competitiveness."

In addition to moderate-to-severe plaque psoriasis, a supplemental New Drug Application (sNDA) for gumokimab in active ankylosing spondylitis has been accepted for review by the Center for Drug Evaluation (CDE) of the NMPA.

About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient, integrated commercialization model, the company has evolved into a globally competitive biopharmaceutical focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 27 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs), 8 innovative drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

Forward-Looking Statements
This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

SINGAPORE, June 11, 2026 /PRNewswire/ -- Trip.com Group Limited (Nasdaq: TCOM; HKEX: 9961), a leading one-stop travel service provider of accommodation reservation, transportation ticketing, packaged tours and corporate travel management, will announce its financial results for the three months ended March 31, 2026 on Wednesday, June 24, 2026, U.S. Time, after the market closes.

Trip.com Group's management team will host a conference call at 8:00 PM U.S. Eastern Time on June 24, 2026 (or 8:00 AM on June 25, 2026 in the Hong Kong Time) following the announcement.

The conference call will be available on Webcast live and replay at: http://investors.trip.com. The call will be archived for twelve months at this website.

All participants must pre-register to join this conference call using the Participant Registration link below:

https://register-conf.media-server.com/register/BI474cf1d2cafe4883828d22dcfc4b7d15.

Upon registration, each participant will receive details for this conference call, including dial-in numbers and a unique access PIN. To join the conference, please dial the number provided, enter your PIN, and you will join the conference instantly.

About Trip.com Group Limited

Trip.com Group Limited (Nasdaq: TCOM; HKEX: 9961) is a leading global one-stop travel platform, integrating a comprehensive suite of travel products and services and differentiated travel content. It is the go-to destination for many travelers in Asia, and increasingly for travelers around the world, to explore travel, get inspired, make informed and cost-effective travel bookings, enjoy hassle-free on-the-go support, and share travel experience. Founded in 1999 and listed on Nasdaq in 2003 and HKEX in 2021, the Company currently operates under a portfolio of brands, including Ctrip, Qunar, Trip.com and Skyscanner, with the mission "to pursue the perfect trip for a better world."

For further information, please contact:

Investor Relations
Trip.com Group Limited
Email: [email protected]

ISTANBUL, June 10, 2026 /PRNewswire/ -- Zoomlion Heavy Industry Science & Technology Co., Ltd. ("Zoomlion") attracted widespread attention at KOMATEK 2026 in Istanbul with the appearance of its humanoid robot Z01. Alongside more than 40 high-end construction machinery exhibits that secured orders exceeding RMB 1 billion, Z01 emerged as one of the event's most talked-about attractions.

Designed for industrial collaboration, intelligent guidance, and educational applications, the bipedal humanoid robot demonstrated coordinated movement and precise operational capabilities throughout the exhibition. During a live demonstration, Z01 performed a Tai Chi routine, showcasing advanced motion control, dynamic balance, and human-robot interaction capabilities, drawing large crowds of visitors.

The debut of Z01 highlights Zoomlion's growing commitment to embodied AI, with embodied AI robots and related emerging industries forming the company's third growth curve.

Zoomlion possesses significant advantages in embodied intelligence development. As one of the earliest companies in China's construction machinery industry to invest in industrial IoT technologies, the company has built a strong digital foundation through Zvalley, its AI-powered industrial internet subsidiary, which is supported by nearly 1,300 technical and R&D professionals.

Since 2024, Zoomlion has accelerated the development of embodied AI technologies through its integrated hardware-software innovation capabilities. The company has established a comprehensive technology framework covering robot hardware, core components, decision-making and motion-control systems, and software ecosystems. At the same time, the integration of AI and robotics technologies is helping drive the intelligent transformation of Zoomlion's construction machinery, agricultural machinery, and mining equipment businesses.

By the end of 2025, Zoomlion had developed eight embodied AI robot prototypes across four major categories, creating a diversified product portfolio that includes humanoid and wheeled robots. Leveraging the company's extensive industrial environments, these robots have been validated in real-world applications at Zoomlion Smart City, including logistics handling, factory inspection, loading and unloading, pre-assembly, and quality inspection. These deployments have provided valuable operational data and experience for future large-scale commercialization.

Earlier this year at Hannover Messe 2026, Zoomlion showcased Robot Ops, its embodied AI development platform, and demonstrated collaborative operations involving humanoid and logistics robots. The event highlighted the company's progress in moving embodied AI from laboratory research to practical, industrial-grade applications, emphasizing real-world adaptability, autonomous decision-making, and multi-robot collaboration.

Today, embodied AI robots are already being utilized across multiple manufacturing processes within Zoomlion Smart City. Zoomlion is committed to developing embodied intelligence with an industrial mindset, focusing on real-world scenarios and building capabilities from the ground up. By establishing a robust industrial data system for embodied AI and advancing engineering-oriented robot design and manufacturing, the company is steadily laying the foundation for the large-scale deployment of embodied intelligence technologies across industries.

Mainland Chinese authorities are poised to invest approximately RMB2 trillion over the next five years to build nationwide data centers to support the domestic AI industry, Citi said in a report that, citing foreign media. Chinese telecom operators will be responsible for operating these data centers and will use at least 80% domestically produced AI accelerators.

In the broker's view, this new initiative will benefit foundries SMIC (00981.HK) and HUA HONG GRACE (01347.HK); OSAT players CHANG ELEC TECH (600584.SH) and TONGFU MICROELECTRONICS (002156.SZ); equipment suppliers ASMPT (00522.HK) and VITAL DEEPTECH (600641.SH); as well as AI accelerator vendors, as it provides a clearer roadmap for China’s AI localization.

The broker expected the target of more than 80% localization of AI chips to be achievable, as domestic AI chipmakers have already effectively captured the vast majority of China’s AI accelerator market share this year, while imports of NVIDIA Corporation (NVDA.US) H200 have largely stalled.

The broker opined this will also be more favorable for small- and mid-sized AI chipmakers, as state-backed data centers are more willing to procure from a broader range of suppliers.
~

AASTOCKS Financial News
Website: www.aastocks.com

BOSTON and SHENZHEN, China, June 10, 2026 /PRNewswire/ -- XtalPi (2228.HK), a leading platform in artificial intelligence (AI) and robotics-driven drug discovery, today announced a strategic partnership with a prominent international biopharmaceutical company. The collaboration focuses on developing a best-in-class small molecule against a G protein-coupled receptor (GPCR). This agreement builds upon a rigorous and successful pilot phase, where XtalPi's integrated quantum physics and AI algorithms delivered breakthrough hit rates, confirming the platform's capacity to tackle this complex metabolic target.

Under the agreement, the partner will provide an upfront payment and fully fund XtalPi's early R&D efforts. In addition, XtalPi is also eligible to receive preclinical, clinical, and commercial milestones, along with future royalties, bringing the total potential deal value to over $400 million. This partnership underscores the industry's strong confidence in XtalPi's scientific infrastructure and reinforces XtalPi's competitive edge and sustainable growth in conquering high-value targets.

Navigating Structural Blind Spots
The specific GPCR target receptor central to this collaboration exhibits extreme conformational plasticity, making its active pockets notoriously difficult for small molecules to selectively engage. Compounding this challenge is the absence of publicly available co-crystal structures of this receptor bound to small-molecule ligands. Operating within this structural blind spot, traditional high-throughput screening (HTS) methods frequently fall short in delivering molecules that satisfy the stringent, multidimensional requirements for potency, subtype selectivity, and oral bioavailability.

To bypass the structural data void with this highly dynamic GPCR, XtalPi's R&D team deployed multiscale enhanced sampling simulations to rigorously map the receptor's functional conformational landscape and implemented a dynamic, multi-conformational screening strategy.

Leveraging advanced quantum physics models and AI algorithms, XtalPi executed highly efficient virtual screening across hundreds of millions of commercial compounds. The company then applied its proprietary XFEP (Free Energy Perturbation) platform for precise binding affinity prediction.

Scaling R&D with a Closed-Loop AI and Robotics Engine
Entering the comprehensive collaboration phase, XtalPi will fully deploy its structure-based rational drug design platform. By seamlessly integrating quantum physics, generative AI, and large-scale automated chemical synthesis orchestrated by a Multi-Agent system, XtalPi will drive rapid Design-Make-Test-Analyze (DMTA) cycles.

This automated laboratory infrastructure bridges the historical gap between computational design and wet-lab synthesis and validation, continuously generating novel drug candidates optimized for high potency and ideal ADMET (absorption, distribution, metabolism, excretion, and toxicity) profiles. Ultimately, this approach aims to significantly expand the druggable chemical space and shorten discovery timelines, accelerating the translation of cutting-edge computational breakthroughs into substantial clinical assets for patients worldwide.

"This collaboration underscores our deep commitment to supporting top-tier biopharmaceutical companies with robust, scalable AI and robotics capabilities," said Dr. Shuhao Wen, Chairman at XtalPi. "At XtalPi, we design our platform to act as the essential infrastructure for innovation—helping our partners reliably translate complex biological challenges into strong pipeline assets. We are excited to combine our technological strengths with our partner's clinical vision to advance accessible, highly effective oral therapies in the metabolic space."

About XtalPi

XtalPi Holdings Limited (XtalPi, 2228.HK) was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.

中國深圳和波士頓2026年6月10日 /美通社/ -- 全球領先的AI+機器人新藥與新材料研發平台晶泰科技（2228.HK）今日宣布，已與一家管線豐富且擁有多款商業化產品的國際知名生物制藥公司達成總額超4億美元的AI藥物發現戰略合作。雙方將針對一個GPCR（G蛋白偶聯受體）靶點，共同開發具備「同類最佳（Best-in-Class）」潛力的創新口服小分子藥物。

根據協議，合作方將向晶泰科技支付首付款並承擔所有的早期研發費用，晶泰科技還將獲得臨床前、臨床及商業化里程碑付款，以及未來的銷售分成，項目潛在總金額超4億美元。這種將近期研發收入與長期管線資產價值深度綁定的合作模式，既有效降低了晶泰科技參與高壁壘靶點研發的成本與風險，又鎖定了重磅藥物的高彈性回報空間。此次合作不僅體現了前沿藥企對晶泰研發實力的深厚信賴，更再次印證了晶泰平台在攻克難成藥、高價值靶點上的競爭優勢與可持續增長能力。

破解復雜 GPCR 的小分子「難成藥」困局

本次合作所聚焦的GPCR靶點存在多亞型動態平衡，其天然結合口袋極難被小分子精準靶向，全球範圍內尚無小分子與其結合的共晶結構的公開報道。面對此類「結構盲區」，傳統的高通量篩選（HTS）難以同時優化活性、選擇性與藥代屬性等核心指標並產出具有競爭力的分子候選，現有在研小分子管線項目均處於早期臨床階段。

面對這一結構生物學難題，晶泰科技利用其先進的計算藥物研發平台，顯著提升了苗頭化合物發現的效率與精度，實現了從傳統「大海撈針」到「智能導航」的轉變，在客戶的先導項目中展現了卓越的創新突破與交付能力。

晶泰團隊以多尺度增強採樣模擬技術成功「解碼」了該靶點的關鍵構象，採用多構象協同篩選策略，顯著提升發現高潛力的活性分子的可能性。在先導項目中，依托先進的量子物理模型與AI算法，晶泰科技對億級規模的商業化化合物庫進行了高效虛擬篩選，並利用XFEP自由能微擾平台精準預測分子親和力，大幅提高篩選分子的命中率，獲得客戶的高度認可，直接促成並加速了本次戰略合作的簽署。

自動化與 AI 引擎：規模化重塑新藥研發範式

進入全面合作後，晶泰科技將啟用其融合量子物理與AI的結構理性藥物設計平台，結合大規模自動化化學合成，全面賦能快速的 DMTA（設計-合成-測試-分析）循環。其自動化實驗室在Multi-Agent的統籌下，源源不斷地產出兼具良好活性，新穎結構及理想藥代動力學（ADMET）屬性的候選分子，大幅擴展可成藥化學空間，並縮短研發周期。雙方的強強聯手，有望加速把尖端計算生物學突破轉化為惠及全球的實質性管線資產。

晶泰科技董事局主席溫書豪博士表示：「此次戰略合作的達成，是晶泰『AI+機器人』底層研發系統在全球頂級生物制藥舞台上的又一次實戰驗證。我們將繼續發揮晶泰的平台優勢，為賦能全球創新藥研發打造『新基建』，將兼具挑戰性與巨大市場價值的生物學難題轉化為具有高潛力的管線資產。期待我們的合作能成功攻堅代謝領域的重磅口服療法，為全球患者帶來更便捷、高效的治療方案。」

關於晶泰科技

晶泰科技（「XtalPi Holdings Limited」，股份簡稱：晶泰控股，XTALPI，股票代碼：2228.HK）由三位麻省理工學院的物理學家於 2015 年創立，是一個基於量子物理、以人工智能賦能和機器人驅動的創新型研發平台。公司採用基於量子物理的第一性原理計算、人工智能、高性能雲計算以及可擴展及標準化的機器人自動化相結合的方式，為制藥及材料科學（包括農業技術、能源及新型化學品以及化妝品）等產業的全球和國內公司提供藥物及材料科學研發解決方案及服務。

• COPD study initiation expands SKB378/WIN378 development into a second major respiratory disease
• SKB378/WIN378 is currently being evaluated in the Phase 2/3 POLARIS asthma study, with initial Phase 2 data expected in the second half of 2026
• SKB378/WIN378 has the potential to be the first-to-market, ultra long-acting anti-TSLP antibody for asthma and COPD, with Phase 3 initiation in asthma planned for Q4 2026

CHENGDU, China, June 9, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company") today announced that its partner Windward Bio has dosed the first patients in the Phase 2 SIRIUS study of SKB378/WIN378 (also known as HBM9378) in patients with chronic obstructive pulmonary disease (COPD).

COPD is a progressive, irreversible lung disease and the third leading cause of death worldwide. Driven by immune-mediated airway inflammation and persistent airflow obstruction, the disease makes even routine daily activities a struggle. Its defining feature is exacerbations — sudden, severe flare-ups that lead to emergency room visits, hospitalizations, and lasting declines in lung function. Despite currently available inhaled background therapies, more than 3 million patients with moderate-to-severe COPD remain at high risk of recurrent exacerbations, underscoring an urgent need for better treatment options.

SIRIUS is a global, Phase 2 randomized, double-blind, placebo-controlled, dose-finding study. It is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SKB378/WIN378 in patients with moderate-to-severe COPD.

SKB378/WIN378 started as a co-development project jointly conducted by the Company and Harbour BioMed, with both parties equally sharing global rights.

About SKB378/WIN378 (also known as HBM9378)

SKB378/WIN378 is a next-generation, fully human monoclonal antibody that potently inhibits the TSLP ligand. This clinically validated target plays a key role in the development and progression of a wide array of immunological diseases, including asthma and COPD. SKB378/WIN378 has been engineered to achieve half-life extension (HLE) and silenced effector function. It has been studied in a Phase 1 trial, which confirmed an extended half-life suitable for twice-yearly dosing, demonstrated a low rate of antidrug antibodies, and was safe and well tolerated up to the highest dose tested. SKB378/WIN378 is administered subcutaneously. Windward Bio licensed the global rights (excluding Greater China and several Southeast and West Asian countries) for SKB378/WIN378 from Kelun-Biotech and Harbour BioMed (also known as HBM9378). WIN378 is currently being evaluated in the POLARIS Phase 2/3 asthma study with initial readouts expected in the second half of 2026. WIN378 is also being evaluated in the SIRIUS Phase 2 COPD study. The first Phase 3 study of WIN378 in asthma is expected to begin in the fourth quarter of 2026.

About Kelun-Biotech 

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/. 

About Windward Bio

Windward Bio is a clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committed to transforming the treatment of people living with serious immunological conditions. Its lead program is WIN378, a potential best-in-disease, ultra long-acting anti-TSLP monoclonal antibody currently in a Phase 2/3 trial for asthma and in a Phase 2 study for COPD. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bispecific with broad therapeutic potential across immunological diseases, which is currently in Phase 1. The company is building a discovery pipeline of long-acting bispecific antibodies, targeting validated biology in respiratory and dermatological conditions.